ImmuCell Corporation

Equities

ICCC

US4525253062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-28 EDT			5-day change	1st Jan Change
4.39 ^USD	-3.20%		-7.77%	-13.75%

05-15	Transcript : ImmuCell Corporation, Q1 2024 Earnings Call, May 15, 2024
04-09	Immucell Corporation Reports Unaudited Sales Results for the Three Months and Twelve Months Ended March 31, 2024	CI

ImmuCell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 21, 2022 at 04:06 pm

ImmuCell Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 0.655078 million compared to net income of USD 0.147764 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to basic earnings per share from continuing operations of USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.08 compared to diluted earnings per share from continuing operations of USD 0.02 a year ago.
For the nine months, net loss was USD 0.825939 million compared to USD 0.152426 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.02 a year ago.

Latest news about ImmuCell Corporation

Transcript : ImmuCell Corporation, Q1 2024 Earnings Call, May 15, 2024	05-15
Immucell Corporation Reports Unaudited Sales Results for the Three Months and Twelve Months Ended March 31, 2024	04-09	CI
ImmuCell Shares Fall After $20 Million Mixed Securities Shelf Filing	04-02	MT
Transcript : ImmuCell Corporation, Q4 2023 Earnings Call, Feb 28, 2024	02-28
ImmuCell Corporation Enters into an Allonge to and Amendment of Line of Credit with Gorham Savings Bank	02-27	CI
ImmuCell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
ImmuCell Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
ImmuCell Corporation Announces Unaudited Sales Results for the Fourth Quarter and Full Year Ended December 31, 2023	01-08	CI
Transcript : ImmuCell Corporation, Q3 2023 Earnings Call, Nov 14, 2023	11-14
ImmuCell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter, Nine Months and Trailing Twelve Months Ended September 30, 2023	23-10-05	CI
Transcript : ImmuCell Corporation, Q2 2023 Earnings Call, Aug 11, 2023	23-08-11
ImmuCell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Immucell Corporation Reports Preliminary Unaudited Sales Results for the Second Quarter, Six Months and Twelve Months Ended June 30, 2023	23-07-11	CI
ImmuCell Adjusts US FDA Submission Schedule for Re-Tain	23-06-28	MT
ImmuCell Corporation Appoints Bryan K. Gathagan to Board of Directors	23-06-21	CI
ImmuCell Corporation Announces Approval of Principal Terms of $3 Million Debt Facility	23-06-15	CI
Transcript : ImmuCell Corporation - Shareholder/Analyst Call	23-06-15
Transcript : ImmuCell Corporation, Q1 2023 Earnings Call, May 12, 2023	23-05-12
ImmuCell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : ImmuCell Corporation, 2022 Earnings Call, Feb 22, 2023	23-02-22
ImmuCell Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-21	CI
Immucell Corporation Provides Earnings Guidance for First Quarter Ending March 31, 2023	23-02-21	CI
David S. Cunningham Intends to Retire from the Board of Directors of David S. Cunningham	23-02-01	CI
ImmuCell Corporation Announces Unaudited Preliminary Sales Results for the Third Quarter and Full Year Ended December 31, 2022	23-01-09	CI

Chart ImmuCell Corporation

Duration

Period

More charts

Company Profile

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Lytham Partners Spring Investor Conference

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUCELL CORPORATION	-13.75%	35.48M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research